

2. Supplementary Tables

2.1 Supplementary Table 1: Cell counts, MM and MMP of the full cohort.

| | Patients developing BI | | P value |
|----------------------------------------|------------------------|-------------------------|---------|
| | in 90 days (N = 97) | in 90 days (N = 138) | |
| Absolute value of CD3+ cells (/ML) | 938.45 ± 645.39 | 1445.82 ± 622.83 | <0.001 |
| Percentage of CD3+ cells (%) | 67.49 ± 13.21 | 73.66 ± 9.58 | <0.001 |
| Absolute value of CD3+CD4+ cells (/ML) | 540.84 ± 415.95 | 849.89 ± 394.69 | <0.001 |
| Percentage of CD3+CD4+ cells (%) | 38.86 ± 12.02 | 43.50 ± 9.36 | 0.001 |
| Absolute value of CD3+CD8+ cells (/ML) | 320.46 ± 250.12 | 476.96 ± 259.49 | <0.001 |
| Percentage of CD3+CD8+ cells (%) | 22.63 ± 9.54 | 24.14 ± 9.13 | 0.22 |
| Ratio of CD4 +T cells to CD8+ T cells | 2.14 ± 1.55 | 2.15 ± 1.16 | 0.95 |
| MM of CD3+ cells | 2.72 ± 1.60 | 2.03 ± 1.35 | <0.001 |
| MM of CD3+CD4+ cells | 3.42 ± 1.89 | 2.75 ± 1.61 | 0.004 |
| MM of CD3+CD8+ cells | 1.64 ± 1.28 | 0.95 ± 0.77 | <0.001 |
| MM of CD3+CD4+CD8+ cells | 3.26 ± 2.28 | 2.57 ± 1.81 | 0.01 |
| MM of CD3+CD4-CD8- cells | 0.83 ± 0.91 | 0.53 ± 0.51 | 0.004 |
| MMP of CD3+ cells | 31.46 ± 10.92 | 37.56 ± 12.06 | <0.001 |
| MMP of CD3+CD4+ cells | 20.29 ± 12.95 | 24.60 ± 13.55 | 0.02 |
| MMP of CD3+CD8+ cells | 42.38 ± 11.58 | 55.59 ± 11.08 | <0.001 |
| MMP of CD3+CD4+CD8+ cells | 29.06 ± 17.57 | 33.23 ± 16.94 | 0.07 |
| MMP of CD3+CD4-CD8- cells | 54.62 ± 18.50 | 63.91 ± 16.06 | <0.001 |

| | Patients developing ACLF in 90 days | | P value |
|----------------------------------------|----------------------------------------|------------------|---------|
| | (N = 29) | (N = 206) | |
| Absolute value of CD3+ cells (/ML) | 626.31 ± 232.72 | 1322.28 ± 677.03 | <0.001 |
| Percentage of CD3+ cells (%) | 65.99 ± 16.14 | 71.84 ± 10.67 | 0.07 |
| Absolute value of CD3+CD4+ cells (/ML) | 366.75 ± 183.52 | 772.38 ± 432.04 | <0.001 |
| Percentage of CD3+CD4+ cells (%) | 38.62 ± 15.56 | 42.00 ± 9.88 | 0.11 |
| Absolute value of CD3+CD8+ cells (/ML) | 204.11 ± 124.08 | 441.68 ± 268.33 | <0.001 |
| Percentage of CD3+CD8+ cells (%) | 21.51 ± 11.89 | 23.80 ± 8.89 | 0.22 |
| Ratio of CD4 +T cells to CD8+ T cells | 2.32 ± 1.56 | 2.12 ± 1.30 | 0.44 |
| MM of CD3+ cells | 3.01 ± 1.21 | 2.22 ± 1.50 | 0.007 |
| MM of CD3+CD4+ cells | 4.04 ± 2.05 | 2.89 ± 1.67 | 0.001 |
| MM of CD3+CD8+ cells | 1.63 ± 0.97 | 1.18 ± 1.07 | 0.03 |
| MM of CD3+CD4+CD8+ cells | 3.14 ± 2.24 | 2.81 ± 2.01 | 0.42 |

| | | | |
|---------------------------|-------------------|-------------------|--------|
| MM of CD3+CD4-CD8- cells | 1.09 ± 0.84 | 0.59 ± 0.68 | 0.005 |
| MMP of CD3+ cells | 29.16 ± 8.72 | 35.87 ± 12.14 | 0.004 |
| MMP of CD3+CD4+ cells | 18.77 ± 10.32 | 23.39 ± 13.75 | 0.08 |
| MMP of CD3+CD8+ cells | 38.28 ± 12.56 | 51.66 ± 12.39 | <0.001 |
| MMP of CD3+CD4+CD8+ cells | 32.20 ± 17.74 | 31.42 ± 17.26 | 0.82 |
| MMP of CD3+CD4-CD8- cells | 47.53 ± 17.28 | 61.84 ± 17.04 | <0.001 |

MM: mitochondrial mass; MMP: mitochondrial membrane potential.